Butyrate has been shown to stimulate GLP-1 secretion, making it a logical choice in a supplement targeting appetite control and satiety
Compared with initiating an SGLT2i, semaglutide OW was associated with significantly greater improvements in weight, BMI, and HbA1c, but with similar all-cause HCRU and medical costs after 1 year
Liraglutide shares 97% sequence homology with human GLP-1 and can bind to and activate GLP-1R.78 The elimination half-life of liraglutide is 13 h, and only one injection per day is required.62 Lixisenatide Lixisenatide was developed by Sanofi to treat T2DM.64,93 Structurally, lixisenatide is based on the exenatide structure but lacks proline at position 38, and six lysines are linked after serine at position 39.94 The six lysine residues increase the rigidity of the molecules structure, thus allowing its drug properties to be improved.78 These changes stabilize its structure, prevent protein degradation of the molecule in the circulation, and increase the circulation time enough to ensure once-daily injection (compared with exenatide, which is injected two or three times daily)
Seeing it laid out like this is illuminating, isn't it
GLP-1s are neither universally good nor bad for IBS
The primary outcomes for the 23 trials are also given in Table 1